Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results
Date:11/4/2008

rating expenses by up to $1 million annually. Stock-based compensation expense, which is included in operating expenses, was $642,000 for the 2008 third quarter compared with $904,000 for the same prior year period.

There was no gain on sale of products for the 2008 third quarter compared with $1.8 million for the same prior year period. The gain on sale of products for the 2007 third quarter related to the receipt of a milestone payment in the amount of $1.8 million due to the achievement of Nipent(R) (pentostatin for injection) sales targets by Mayne Pharma (acquired by Hospira, Inc. in February 2007).

Loss from operations for the 2008 third quarter was $1.1 million compared with $1.3 million for the same prior year period. The Company reported a net loss for the 2008 third quarter of $569,000, or $0.01 per fully diluted share, compared with net income of $192,000, or $0.00 per fully diluted share, for the same prior year period. The net loss for the 2008 third quarter includes an income tax benefit of $42,000 compared with $427,000 for the same prior year period.

"In a troublesome economic climate, particularly for biotechnology companies in SuperGen's valuation range, our third quarter and year-to-date financial performance was positive," said James S. Manuso, Ph.D., President and Chief Executive Officer. "Our cash, cash equivalents and marketable securities at the end of the third quarter was approximately $88.7 million dollars. We continue to manage our financial resources to maximize the impact every dollar has on our drug discovery and development objectives. Our operational results for the quarter include the clinical advancement of MP-470, our oral tyrosine kinase inhibitor, and further preparations for entering SGI-1776, our oral PIM kinase inhibitor, into Phase 1 clinical trials."

Total revenues for the nine months ended September 30, 2008 were $26.5 million compared with $15.2 million for the same prior year period. Total rev
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... NY (PRWEB) , ... July 03, 2015 , ... Cuvettes have been used in countless ... style catalog to find the cuvette they needed. As expected, this was a daunting ... order the wrong part because they were not able to navigate the complex catalog structure. ...
(Date:7/2/2015)... ... 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), ... today the acquisition of Turner Medical, Inc ., thus becoming a global ... the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product ...
(Date:7/1/2015)... AURORA, Colo. and BANGALORE, India ... a global genomic profiling company that uses next generation ... appointment of Scott A. Storrer as chief ... and CEO, he will be responsible for all strategy, ... Vijay Chandru , who has served as Strand,s chairman ...
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... 14 Stemedica Cell Technologies, Inc., a world leader ... that it has completed its proprietary master bank of ... was manufactured in accordance with FDA Good Manufacturing Practices ... necessary safety testing required by the FDA and is ...
... (NYSE Amex: NBS ), an international biopharmaceutical ... that Chief Executive Officer, Robin Smith, M.D., MBA, will present ... 12th Annual Healthcare Conference at the New York Palace Hotel ... Dr. Smith is scheduled to present on Monday, September 13th, ...
... Sept. 13 Champions Biotechnology, Inc. (OTC Bulletin Board: ... advanced preclinical platforms and tumor specific data to enhance the ... the fiscal 2011 first quarter ended July 31, 2010.  Full ... the Company,s Form 10-Q at www.championsbiotechnology.com . ...
Cached Biology Technology:Stemedica Announces Completion of Clinical Stem Cell Master Bank 2NeoStem to Present at Rodman & Renshaw's 12th Annual Healthcare Conference 2Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 4
(Date:6/26/2015)... Utah , June 26, 2015 ATL Technology, ... and devices with specialties in single use solutions, headquartered in ... of MedConx, Inc. (a California corporation ... and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Sharp has selected its industry-leading Natural ... its latest flagship smartphone device, the AQUOS ZETA ... shipments of its fingerprint ID sensor technology, this ... and leadership in the biometrics market through its ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... estimated 5 percent of the Key West, Fla., population ... dengue virus in 2009, according to a report from the ... Department of Health. After three initial locally acquired cases ... and the Florida Department of Health conducted a study to ...
... Kolls, Professor and Chairman of Genetics at the LSU Health ... a $2.1 million grant over five years by the National ... Health to determine the role and identify which T-helper cells ... which can be a complication of HIV/AIDS. It can also ...
... In any battle, sizing up one,s opponent is ... infection, that means assessing every nook and cranny of ... At the Center for Biological Research of the ... they hope will take out bacteria at their molecular ...
Cached Biology News:Report suggests nearly 5 percent exposed to dengue virus in Key West 2LSUHSC awarded $2 million dollar grant to prevent pneumonia linked to immune deficiency 2In the ring: Researchers fighting bacterial infections zero in on microorganism's soft spots 2In the ring: Researchers fighting bacterial infections zero in on microorganism's soft spots 3
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
Biology Products: